TRACON PHARMACEUTICALS INC's ticker is TCON and the CUSIP is 89237H209. A total of 34 filers reported holding TRACON PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $110,314 | -49.0% | 619,740 | -16.6% | 0.00% | – |
| Q2 2023 | $216,238 | -80.6% | 743,088 | +25.7% | 0.00% | – |
| Q1 2023 | $1,117,028 | +26.8% | 591,020 | 0.0% | 0.00% | – |
| Q4 2022 | $880,619 | -10.7% | 591,020 | +0.1% | 0.00% | – |
| Q3 2022 | $986,000 | -16.5% | 590,688 | 0.0% | 0.00% | – |
| Q2 2022 | $1,181,000 | -24.0% | 590,688 | 0.0% | 0.00% | – |
| Q1 2022 | $1,554,000 | -18.8% | 590,688 | -14.5% | 0.00% | – |
| Q4 2021 | $1,913,000 | -28.9% | 690,622 | -0.6% | 0.00% | – |
| Q3 2021 | $2,689,000 | -39.9% | 694,859 | +0.8% | 0.00% | – |
| Q2 2021 | $4,472,000 | -21.6% | 689,038 | -0.6% | 0.00% | – |
| Q1 2021 | $5,705,000 | +56.6% | 693,216 | +122.7% | 0.00% | – |
| Q4 2020 | $3,643,000 | +4757.3% | 311,341 | +2040.4% | 0.00% | – |
| Q3 2020 | $75,000 | +158.6% | 14,546 | 0.0% | 0.00% | – |
| Q2 2020 | $29,000 | +16.0% | 14,546 | 0.0% | 0.00% | – |
| Q1 2020 | $25,000 | -26.5% | 14,546 | 0.0% | 0.00% | – |
| Q4 2019 | $34,000 | – | 14,546 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 4,125,322 | $8,251,000 | 3.72% |
| Ikarian Capital, LLC | 2,788,853 | $5,577,000 | 1.02% |
| Telemetry Investments, L.L.C. | 100,000 | $200,000 | 0.24% |
| ACT CAPITAL MANAGEMENT, LLC | 28,500 | $57,000 | 0.08% |
| JOHNSON & JOHNSON | 84,003 | $168,000 | 0.04% |
| NEA Management Company, LLC | 346,719 | $693,000 | 0.04% |
| X-Square Capital, LLC | 17,973 | $36,000 | 0.02% |
| BOOTHBAY FUND MANAGEMENT, LLC | 268,301 | $537,000 | 0.01% |
| LINDEN ADVISORS LP | 454,916 | $910,000 | 0.01% |
| DOWLING & YAHNKE LLC | 47,455 | $95,000 | 0.00% |